Table I.
Single agent IMC-A12 results for rapamycin and IMC-A12 in tested xenografts1
| Xenograft | Panel | KM Estimate of Median Time to Event | P-value | EFS T/C | Response |
|---|---|---|---|---|---|
| EW5 (R) | Ewing | 26.4 | <0.001 | 4.9 | PD2 |
| EW5 (IMC) | Ewing | 17.6 | <0.001 | 2.6 | PD2 |
| Rh28 (R) | ALV RMS | 18.8 | 0.282 | 1.2 | PD1 |
| Rh28 (IMC) | ALV RMS | > EP | <0.001 | > 2.8 | MCR |
| Rh30 (R) | ALV RMS | 28.9 | <0.001 | 2.4 | PD2 |
| Rh30 (IMC) | ALV RMS | 30.5 | 0.004 | 2.3 | PD2 |
| Rh41 (R) | ALV RMS | 11.7 | <0.001 | 1.7 | PD2 |
| Rh41 (IMC) | ALV RMS | 38.6 | <0.001 | 3.3 | PD2 |
| NB-1643 (R) | Neuroblastoma | 19.7 | 0.028 | 1.3 | PD1 |
| NB-1643 (IMC) | Neuroblastoma | 26.3 | <0.001 | 4.2 | PD2 |
| NB-EBc1 (R) | Neuroblastoma | 24.7 | 0.019 | 2 | PD2 |
| NB-EBc1 (IMC) | Neuroblastoma | 11 | 0.041 | 2 | PD2 |
| OS-2 (R) | Osteosarcoma | > EP | <0.001 | > 2.7 | PD2 |
| OS-2 (IMC) | Osteosarcoma | 34.2 | <0.001 | 2.1 | PD2 |
| OS-9 (R) | Osteosarcoma | > EP | 0.002 | > 1.3 | PD2 |
| OS-9 (IMC) | Osteosarcoma | > EP | <0.001 | > 2.3 | PD2 |
| GBM2 (R) | Glioblastoma | 18.5 | <0.001 | 2.6 | PD2 |
| GBM2 (IMC) | Glioblastoma | 21.7 | <0.001 | 1.4 | PD1 |